Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology

2189 - Usefulness of the first screening using apolipoprotein A2 isoforms as the enrichment strategy for pancreatic cancer and its risk diseases

Date

21 Oct 2018

Session

Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology

Presenters

Yu Sato

Citation

Annals of Oncology (2018) 29 (suppl_8): viii205-viii270. 10.1093/annonc/mdy282

Authors

Y. Sato1, T. Kobayashi1, S. Nishiumi1, S. Okaya2, M. Yoshida1, Y. Kodama1, K. Nagashima3, K. Honda4

Author affiliations

  • 1 Gastroenterology, Kobe University Graduate School of Medicine, 650-0017 - Kobe/JP
  • 2 Department Of Biomarkers For Early Detection Of Cancer, National Cancer Center Research Institute, 104-0045 - Tokyo/JP
  • 3 Research Center For Medical And Health Data Science, The Institute of Statistical Mathematics., 190 - Tokyo/JP
  • 4 Department Of Biomarkers For Early Detection Of Cancer, National Cancer Center Hospital, 104-0045 - Tokyo/JP
More

Resources

Abstract 2189

Background

We recently reported the usefulness of apolipoprotein A2 isoforms (apoA2-i) as a plasma/serum biomarker for the early detection of pancreatic cancer (PC) and its risk diseases, and the level of ApoA2-ATQ/AT, which is one of apoA2-i, was significantly decreased in early stage PC and risk diseases. To evaluate the possibility of usefulness as the screening biomarker, we prospectively tested the performance of ApoA2-ATQ/AT as a first screening method for PC and its risk diseases in general population.

Methods

Study participants were prospectively enrolled from the subjects of medical checkup at 6 institutions between Oct 2015 and Jan 2017. We measured the plasma level of ApoA2-ATQ/AT by using ELISA, and all participants with the positive results from the level of ApoA2-ATQ/AT (ApoA2-ATQ/AT < 35 μg/mL) were recommended for 2nd examination with contrast enhanced-CT (CECT), MRI, or EUS.

Results

Among a total of 5,120 participants registered in this study, 83 were positive (Positive rate: 1.6%). In the 83 subjects with the positive results, 55 (66.3%) underwent 2nd examination. Finally, pancreatic diseases were detected in 23 (41.8%) of 55. They included 1 PC, 12 pancreatic cystic lesions (PCL), and 3 chronic pancreatitis (CP). Furthermore, 14.5% of ApoA2-ATQ/AT positive subjects had abnormal ultrasonographic findings in the pancreas, while the subjects with ultrasonographic abnormalities of the pancreas under a medical checkup were 3.2% of the participants who underwent transabdominal ultrasonography. Taken together, ApoA2-ATQ/AT could significantly accumulate the subjects with abnormal ultrasonographic findings by 4.53 times in comparison with a normal medical checkup for general population.

Conclusions

Plasma ApoA2-ATQ/AT as a first screening method in general population could improve an efficiency of detection of PC and its high-risk diseases.

Clinical trial identification

Legal entity responsible for the study

Kobe University Graduate School of Medicine, Department of Gastroenterology.

Funding

Japan Agency for Medical Research and Development.

Editorial Acknowledgement

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings